MERCANS
22.12.2023 15:10:28 CET | Business Wire | Press release
Avasant, a globally recognized analyst firm, has named Mercans as a payroll process transformation leader in its annual RadarView assessment of 2022-2023. Mercans clearly stood out among the 27 providers assessed for consistently delivering exceptional value to the market. Avasant's comprehensive industry analysis categorizes providers into challengers, disruptors, innovators, and leaders. Avasant placed Mercans in an elite group of industry leaders, confirming its technology leadership role in the global payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231222991924/en/
Mercans Emerges as a Payroll Business Process Transformation Leader in Avasant's RadarView (Photo: AETOSWire)
In a span of one year, Mercans transitioned from a disruptor to an industry leader in Avasant’s assessment, demonstrating its impressive progress across all RadarView’s critical excellence dimensions - practice maturity, domain ecosystem, and investments and innovation.
Avasant's meticulous research methodology, incorporating publicly available information, SEC filings, annual reports, executive interviews, product demos, and direct inputs from service providers, adds depth and credibility to the acknowledgment of Mercans' industry leadership.
Avasant highlights Mercans' strategic approach and states: Leveraging its proprietary payroll engine and in-house local experts, Mercans delivers services across 160 countries. Mercans boasts a distinctive practice size, serving multinational corporations and Fortune 500 companies, supporting over 40 languages. The company's global delivery infrastructure spans 121 local offices, contributing to an impressive payroll revenue growth of over 30% from June 2022 to June 2023, reflecting its financial robustness.
At the heart of Mercans' success lies its proprietary global payroll platform - HR Blizz, the only gross-to-net payroll application that allows generating statutory compliant payrolls worldwide in a single software.
Mercans has disrupted the global payroll landscape with its G2N Nova global payroll engine. This state-of-the-art payroll engine stands out as the sole stateless application globally, swiftly generating payroll calculations across 160 countries within seconds, all while avoiding the storage of any sensitive employee data. This innovative approach has positioned G2N Nova as a catalyst for multinational corporations seeking to fully digitize their global payroll operations. Beyond its uniqueness as the sole global gross-to-net payroll application, G2N Nova offers a fully autonomous and touchless payroll experience, leading to dramatic reductions in processing times and costs.
Aditya Jain, Principal Analyst at Avasant, comments, "Mercans has developed its native global payroll engine to facilitate gross-to-net payroll calculations, digitalize processes, and offer self-service functionality to employees in 160 countries worldwide. Its partnerships with HCM and ancillary HR platform vendors enable it to offer comprehensive HR services through a unified portal. It leverages its local delivery network, including offices and regional experts in 121 countries, to help enterprises reduce dependence on local payroll aggregators for last-mile services across countries.
"Its continued investments in technology innovation, such as no-code HR integration tools and instant payments functionality, flexible business models, and a global delivery network, have made Mercans a leader in Avasant’s Payroll Business Process Transformation 2023–2024 RadarView."
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222991924/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom